(OCDX) – Press Releases
-
Quidel and Ortho Announce Expected Closing of Ortho Transaction
-
Quidel and Ortho Announce Expected Closing of Ortho Transaction
-
Ortho Clinical Diagnostics Shareholders Approve Quidel Transaction
-
Ortho Clinical Diagnostics Reports First Quarter 2022 Results
-
Ortho Clinical Diagnostics Recognized with Fifth Prestigious Edison Award for Highly Accurate COVID-19 Solution
-
Ortho Clinical Diagnostics to Report First Quarter 2022 Results on May 4, 2022
-
Ortho Clinical Diagnostics Wins Bronze Stevie® Award for Customer Service and Support
-
Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2021 Results
-
Ortho Clinical Diagnostics Holdings Plc (“Ortho”): Notice of UK Court Scheme Directions Hearing
-
Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021
-
Ortho Clinical Diagnostics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
-
ORTHO CLINICAL DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OCDX and Encourages Investors to Contact the Firm
-
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics
-
Ortho Clinical Diagnostics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
-
Ortho Clinical Diagnostics Reports Third Quarter 2021 Results
-
Ortho Clinical Diagnostics to Report Third Quarter 2021 Results on November 3, 2021
-
Ortho Customers Rank Company No. 1 in Service and Support for Sixth Consecutive Year
-
Ortho Clinical Diagnostics Announces Launch of New ISXM Capabilities
-
Ortho Clinical Diagnostics Announces Closing of Secondary Offering of Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
-
Ortho Clinical Diagnostics Announces Pricing of Secondary Offering of Ordinary Shares
-
Ortho Clinical Diagnostics Announces Secondary Offering of Ordinary Shares
-
Ortho Clinical Diagnostics to Participate in September Investor Conferences
-
Ortho Clinical Diagnostics Expands COVID-19 Test Offerings with Emergency Use Authorization (EUA) of Total Nucleocapsid Antibody Test
-
Ortho Clinical Diagnostics Reports Second Quarter 2021 Results
-
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in Canada
-
Ortho Clinical Diagnostics to Report Second Quarter 2021 Results on August 4, 2021
-
Ortho Clinical Diagnostics Announces Launch of the Interleukin-6 (IL-6) Reagent Pack, Latest Addition to Ortho's Critical Care Blood Testing Menu
-
Ortho Clinical Diagnostics' Quantitative COVID-19 IgG Antibody Test First to Receive FDA Emergency Use Authorization
-
Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific
-
ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico
-
Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response
-
Ortho Clinical Diagnostics to Present at Upcoming Investor Conferences
-
Ortho Clinical Diagnostics Reports First Quarter 2021 Results
-
Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark
-
Global Transfusion Medicine Leader Ortho Clinical Diagnostics Launches Next Gen ORTHO VISION® Swift Platform
-
Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing
-
Ortho Clinical Diagnostics to Report First Quarter 2021 Results on May 5, 2021
-
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media
-
Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense
-
Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data
-
REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results
-
Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results
-
Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results
-
Ortho Clinical Diagnostics to Report Fourth Quarter and Full Year 2020 Results on March 18, 2021
-
Ortho Clinical Diagnostics Names Evelyn Dilsaver to Board of Directors
-
Ortho Clinical Diagnostics Announces Rating Upgrades by S&P Global and Moody’s
-
Ortho Clinical Diagnostics Amends Credit Agreement to Extend Maturity and Increase Borrowing Capacity Under its Revolving Credit Facility
-
Ortho Clinical Diagnostics Announces Closing of Full Over-Allotment Option from Initial Public Offering
-
Ortho Clinical Diagnostics Announces Pricing of Initial Public Offering
Back to OCDX Stock Lookup
